What Lompasar Treats: Main Uses and Benefits

Lompasar (Folic Acid 5 mg) generally provides supportive therapeutic benefit by addressing vital nutritional deficits and offering assistance during phases of high biological demand. The medication is applied across three primary clinical domains that may ease patient burden and support risk management.

---

The medication is commonly used to manage megaloblastic anemia related to systemic imbalance, to manage the risk of serious Neural Tube Defects (NTDs) in the periconceptional period, and is applied in clinical settings involving specific drug treatments, such as methotrexate. This application contributes to easing the symptom burden on the patient, helping address distressing and disruptive symptoms like chronic fatigue, weakness, painful mouth ulcers, and associated gastrointestinal issues.

“The use of the medication is focused on providing supportive relief during symptomatic periods and assists with maintaining functional stability.”

---

Quick Fact: Relief for Systemic Imbalance

Lompasar supports the maintenance of energy and physical comfort by managing symptoms related to systemic imbalance caused by the deficiency, helping patients cope more steadily with fatigue and weakness that create noticeable interference with daily functioning.

Eligibility Map: Who can and cannot use Lompasar — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and children over 1 year; women at high risk for neural tube defects; prophylaxis in chronic hemolytic states and renal dialysis patients.
Populations for whom use is not recommended (if applicable)	The 5 mg tablet is not recommended for infants or very young children; long-term use is not recommended for the elderly unless B12 deficiency is ruled out.
Populations for whom use is contraindicated	Patients with hypersensitivity to Folic Acid or excipients; untreated cobalamin (Vitamin B12) deficiency or undiagnosed megaloblastic anemia; malignant disease (unless for confirmed folate deficiency); and those with rare hereditary sugar intolerances.

---

Key Eligibility Classifications

Category	Official Regulatory Statement
Age-related eligibility rules	Adults are eligible. Children over 1 year are eligible, but infants are eligible by weight and require an alternative formulation.
Pregnancy and lactation eligibility status (if explicitly documented)	Permitted (Category A) for use during both pregnancy and lactation, especially for high-risk indications.
Eligibility-related restrictions	Use requires caution in patients who may have folate-dependent tumors.

---

Connection to the overall eligibility profile: Regulatory documents strictly define eligibility based on the critical exclusionary principle: Folic Acid must not be used alone to treat undiagnosed megaloblastic anemia, due to the severe neurological risks associated with masked Vitamin B12 deficiency. Eligibility is otherwise governed by allergy status, the presence of specific comorbidities, and the suitability of the 5 mg tablet formulation for different age groups.

Interactions with other medicines and products

Lompasar (Folic Acid 5 mg) has formally documented interaction patterns that are specified in regulatory labeling, primarily involving medications used for epilepsy and certain antifolate agents.

Documented Drug-Drug Interactions

Interacting Substance Category	Official Interaction Outcome
Anticonvulsants (e.g., Phenytoin, Primidone, Phenobarbital)	Folic Acid is documented to antagonize the anticonvulsant action; co-administration may result in decreased anticonvulsant plasma levels and potential loss of seizure control.
Antifolate Agents (e.g., Methotrexate, Pyrimethamine)	Folic Acid may reduce the effects of antifolate medicines. However, Folic Acid is also intentionally co-administered with Methotrexate in certain contexts to reduce the risk of toxic adverse reactions.
Absorption-Reducing Agents (e.g., Sulfasalazine, Cholestyramine, Antacids)	Co-administration may reduce the absorption of Folic Acid, which may necessitate a specific separation of administration timing.

Other Official Interaction Constraints

Official labeling mandates specific conditions for co-administration:

• Timing Separation Rules: Folic Acid must be taken at least two hours after aluminum or magnesium-containing antacids, and must be separated by four to six hours from cholestyramine to maintain expected absorption.
• Procedural Interference: Certain antibiotics, such as chloramphenicol, are documented to interfere with the laboratory assay used to measure folate levels, which may result in falsely low diagnostic results.
• Population Restriction: Long-term therapy with Folic Acid at doses exceeding 0.1 mg daily is officially contraindicated in patients with untreated Vitamin B12 deficiency (pernicious anemia), as it may mask the blood disorder while allowing severe neurological damage to progress.

The mechanism of Folic Acid (Lompasar) is centered on its critical role as a metabolic precursor, which, once activated, functions as an essential co-enzyme in fundamental biosynthetic pathways.

Folic Acid requires activation by the enzyme Dihydrofolate Reductase ( DHFR) to form tetrahydrofolate ( THF) cofactors. These cofactors do not modulate receptors but act as essential carriers of one-carbon units within the cell. This initial enzymatic process provides the necessary co-enzymes for metabolic reactions requiring one-carbon transfer.

The active THF derivatives directly support nucleotide synthesis by engaging enzymes like Thymidylate Synthase. By facilitating the creation of the DNA and RNA building blocks (Purines and Thymine), the mechanism is fundamental to genetic material synthesis and is required for mitosis (cell division). This action influences the maturation of cells, particularly those in rapidly reproducing tissues.

This mechanism is crucial for the Hematopoietic System and is required for the proliferation of precursor cells in the bone marrow, thus influencing the morphology of red blood cells. However, the pathway is interdependent; the function of the folate co-enzyme is absolutely dependent on Vitamin B12 (Cobalamin) for the essential homocysteine recycling step, a dependency that presents a key limitation to the mechanism.

Official Administration Guidelines for Lompasar

Lompasar (Folic Acid 5 mg) is administered orally and must be swallowed whole with a drink of water. The tablet can be taken with or without food, establishing a flexible time-relationship with meals.

Dosage Regimens and Frequency

The standard regimen for adults and children over one year is typically 5 mg once daily for high-strength supplementation. For cases involving severe malabsorption, the dose may be increased, potentially up to 15 mg daily. While a daily schedule is most common for therapeutic use, certain prophylactic and maintenance regimens may follow a once weekly pattern.

Administration Scope	Official Guidelines
Route of Administration	Oral (Tablet).
Standard Dosing	5 mg once daily (Adults/Children >1 Year).
Frequency Pattern	Daily or Weekly (maintenance/prophylaxis).

Use Patterns and Procedural Rules

Treatment duration is defined by the underlying condition. For instance, the initial course for anaemia is typically four months, whereas use for chronic conditions (e.g., ongoing renal dialysis) may extend to long-term maintenance. When used for the prevention of Neural Tube Defect recurrence in high-risk patients, the regimen begins before conception and continues throughout the first trimester.

Antacids containing aluminium or magnesium must be taken at least two hours after Lompasar to mitigate reduced absorption. If a daily dose is missed, a double dose should not be taken; the patient should continue with the next scheduled dose. For infants (up to one year), a liquid formulation is usually prescribed, with dosing calculated based on body weight.

Lompasar: Recent Clinical Evidence

---

Evidence for Managing Folate-Related Anemia and Deficiency

Research exploring the use of high-dose Folic Acid for systemic folate deficiency includes Randomized Controlled Trials (RCTs) and observational studies. These studies primarily monitored hematological endpoints, such as red blood cell folate concentration, and also tracked patient-reported outcomes describing discomfort like chronic fatigue and weakness. Studies reported shifts in these markers and associated symptom patterns following supplementation. However, the evidence primarily focuses on short-term physiological correction of the deficit, and long-term effects regarding maintenance requirements are not fully established. Research notes the critical need to differentiate this context from co-existing Vitamin B12 deficiency in trials.

Evidence for Reducing Risk of Neural Tube Defects (NTDs)

The evidence base for this application relies on large-scale RCTs that largely focused on a similar high-dose (4 mg) in high-risk women during the periconceptional period. Research examined the incidence of Neural Tube Defects (NTDs) in offspring. Studies reported that the rate of NTD occurrence in supplemented groups was lower compared to controls. The 5 mg dose is extrapolated from this robust evidence base, although limited direct RCT evidence exists specifically comparing the 5 mg dose to lower doses in the high-risk setting.

Evidence for Supportive Use with Methotrexate Therapy

The research examining the use of Lompasar alongside methotrexate (MTX) primarily consists of Double-blind RCTs. Research was conducted to explore the association between the supplement and specific side effects observed during MTX therapy for chronic inflammatory conditions. Studies reported that groups receiving supplementation had a pattern of lower rates of elevated liver enzymes compared to those receiving placebo, and the use was associated with higher rates of patient treatment continuation.

Research Gaps and Study Limitations

The evidence landscape highlights areas of ongoing research. Comparative evidence is lacking for the 5 mg dose versus lower doses for NTD risk reduction. Furthermore, data for certain groups remain insufficient, as the evidence surrounding MTX therapy primarily focused on adults with rheumatoid arthritis and psoriasis, leaving subgroup findings uncertain for other patient groups or specific comorbidities.

Common questions about Lompasar (FAQ)

Q: How does Lompasar differ from other common medicines used for the same condition?

Official guidelines indicate that Lompasar is provided in a higher dosage (5 mg) of the active ingredient, Folic Acid. This high-strength formulation is generally indicated for use in specific situations, such as confirmed deficiency, malabsorption issues, or required prophylaxis, differentiating it from standard, lower-dose over-the-counter supplements.

Q: Is Lompasar the generic name or the brand name?

Lompasar is the trade name given to the medicine by the manufacturer. The active ingredient it contains is Folic Acid, which is its official generic name and the name used in most regulatory documents.

Q: How long will I need to take this?

The required duration of use is highly dependent on the condition being addressed. For example, an initial course for certain types of anemia may last around four months, whereas use for chronic conditions (like ongoing dialysis) may extend to long-term maintenance.

Q: Are there any serious or rare side effects that have been reported with Lompasar?

Regulatory safety documents describe that official surveillance systems collect information on Serious Adverse Events (SAEs), such as reports of Renal failure or Sepsis. Less frequently, rare reactions like serious allergic reactions (e.g., rash, anaphylaxis) have also been documented.

Q: What happens if I forget to take a dose of Lompasar?

If a dose is forgotten, the official instruction is to continue with the next scheduled dose at the usual time. Regulatory guidance specifies that a double dose should not be taken to make up for a missed one.

Q: Are there specific foods or beverages that should be avoided while taking Lompasar?

While the tablet can be taken with or without food, official regulatory text notes that ethanol (alcohol) may increase the elimination rate of the active ingredient. Additionally, the medicine must be taken at a separate time from antacids containing aluminum or magnesium to avoid affecting its absorption.

Q: Can Lompasar be taken at the same time as over-the-counter pain relievers?

Official government guidance states that this medicine is generally compatible with common over-the-counter painkillers like paracetamol. However, official documents note that when taking certain other prescribed drugs (e.g., methotrexate), the use of specific anti-inflammatory drugs (NSAIDs) is an area where caution is defined.

Q: Is it normal to feel a certain side effect (e.g., mild fatigue) when first starting Lompasar?

Regulatory safety information lists categories of reported adverse reactions, including Gastrointestinal disorders (like abdominal distension) and sometimes Nervous system disorders. Official safety documents list these reactions as possible events that may be reported in patients when beginning treatment.

Q: What is the recommended storage temperature for Lompasar?

Official instructions state that Lompasar must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F and 77 F). The medicine must also be protected from environmental factors like light and moisture.

Q: How should I dispose of unused or expired Lompasar?

Unused or expired medicine must not be disposed of via household trash or by flushing it down the toilet, as this can affect wastewater. Official regulations describe that patients should consult a pharmacist regarding the proper disposal method.

Q: How does Lompasar's active ingredient differ from other similar-sounding drugs (e.g., Folic Acid vs. Folate)?

Lompasar contains the synthetic form, Folic Acid, which is chemically different from the naturally occurring form, folate, found in foods. Research suggests that the synthetic Folic Acid used in this medicine has higher bioavailability (meaning it is better absorbed by the body).

Q: How quickly does the body process Lompasar after it is taken?

Official pharmacokinetic data describes how the body handles the medicine. This data indicates that the active ingredient is rapidly absorbed from the gastrointestinal tract and is subsequently widely distributed throughout the body's tissues.

Q: Does Lompasar interact with any common herbal supplements or vitamins?

Regulatory guidance notes caution regarding interactions with specific supplements. For example, it suggests caution when taking supplements containing Zinc, and notes that high-dose Niacin (another B-vitamin) may affect its overall metabolism.

Q: Can Lompasar affect my ability to drive or operate machinery?

Regulatory documentation, which assesses the medicine's impact on concentration and coordination, states that there is no known effect on a patient's ability to drive or safely operate machinery.

Q: How long does Lompasar stay in your system after the last dose?

Folic acid is a water-soluble vitamin. Amounts in excess of body requirements are handled by normal metabolic processes. The excess amount is primarily eliminated from the body as folate metabolites and unchanged in the urine.

Q: Are there any reported interactions between Lompasar and caffeine?

Studies have noted a possible association between consumption of caffeinated beverages and a negative influence on serum folate levels. This relationship is attributed to caffeine potentially affecting elimination or other metabolic pathways.

Q: How is the safety profile of Lompasar generally described by regulatory agencies?

The active ingredient is generally described by regulatory documents as well tolerated. Undesirable effects are reported to be observed on rare occasions, typically involving mild issues like gastrointestinal disturbance or allergic reactions.

Q: Can Lompasar interact with common blood thinners or anti-coagulants?

Official interaction data documents that the active ingredient is generally not observed to have a significant clinical interaction with common oral anticoagulants, such as warfarin, concerning effects on INR levels. Official documentation notes that caution is sometimes related to high Vitamin K content in certain supplements.

Q: Does the time of day matter when taking Lompasar?

The regulatory administration guide emphasizes flexibility, stating that the tablet can be taken with or without food. This guide does not mandate or recommend a specific time of day for the medicine to be administered.

Storage Conditions

Lompasar (Folic Acid 5 mg) must be stored at Controlled Room Temperature, specifically maintained between 20 C and 25 C (68 F and 77 F). The product must be stored in its original container and kept out of the sight and reach of children.

To preserve product stability, the tablets require protection from environmental factors, including light and moisture. The medicine must not be frozen and should not be stored above 25 C. The tablets should not be used past the expiration date marked on the packaging.

Disposal Instructions

Unused or expired Lompasar must not be disposed of via household waste or by flushing down the toilet (wastewater). Official regulations require consultation with a pharmacist regarding the proper method for discarding medicines no longer needed.